Semi-quantification and Potency Verification of the HIV Protease Inhibitor Based on the Matrix-Capsid Protein Immobilized Nickel (II)/NTA-Tol/Graphene Oxide/SPCE Electrochemical Biosensor

[Image: see text] Human immunodeficiency virus (HIV) causing acquired immune deficiency syndrome (AIDS) is still a global issue.

Long-term drug treatment and nonadherence to medication increase the spread of drug-resistant HIV strains.

Therefore, the identification of new lead compounds is being investigated and is highly desirable.

Nevertheless, a process generally necessitates a significant budget and human resources.

In this study, a simple biosensor platform for semi-quantification and verification of the potency of HIV protease inhibitors (PIs) based on electrochemically detecting the cleavage activity of the HIV-1 subtype C-PR (C-SA HIV-1 PR) was proposed.

An electrochemical biosensor was fabricated by immobilizing His6-matrix-capsid (H(6)MA-CA) on the electrode surface via the chelation to Ni(2+)-nitrilotriacetic acid (NTA) functionalized GO.

The functional groups and the characteristics of modified screen-printed carbon electrodes (SPCE) were characterized by Fourier transform infrared (FTIR) spectroscopy, scanning electron microscopy (SEM), and energy-dispersive X-ray spectroscopy (EDS).

C-SA HIV-1 PR activity and the effect of PIs were validated by recording changes in electrical current signals of the ferri/ferrocyanide redox probe.

The detection of PIs, i.e., lopinavir (LPV) and indinavir (IDV), toward the HIV protease was confirmed by the decrease in the current signals in a dose-dependent manner.

In addition, our developed biosensor demonstrates the ability to distinguish the potency of two PIs to inhibit C-SA HIV-1 PR activities.

We anticipated that this low-cost electrochemical biosensor would increase the efficiency of the lead compound screening process and accelerate the discovery and development of new HIV drugs.